Abstract
Global Initiative for Asthma (GINA) recently recommends clinicians to reduce inhaled corticosteroid doses in patients with severe asthma who respond positively to monoclonal antibodies (MAbs). As we operated this reduction even before the document, we analysed our cohort of subjects on treatment with a MAbs for at least 24 months. Data stored in our electronic archive and at the 6-month follow-up (FU) were registered and patients' adherence to asthma therapy was derived by electronic pharmacy claim database. Sixty-three subjects were enrolled. A complete asthma remission and reduction to GINA Step 3 was obtained in 41% and 61% of them, respectively. Non-adherent subjects to inhaled and oral asthma therapy were 45% of them, with a higher percentage among those in complete remission (59% vs 33%). In our cohort, stepping down asthma therapy from 5 to 3 level in severe asthmatic patients on Mabs is without any negative consequences on asthma control, even in the case of non-adherence.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call